TEVA - Teva Pharmaceutical Industries Limited

NYSE - NYSE Delayed price. Currency in USD
17.82
+0.11 (+0.62%)
At close: 4:01PM EDT
Stock chart is not supported by your current browser
Previous close17.71
Open17.85
Bid0.00 x 0
Ask0.00 x 0
Day's range17.72 - 17.99
52-week range10.85 - 33.82
Volume8,379,213
Avg. volume12,869,712
Market cap18.121B
Beta1.02
PE ratio (TTM)N/A
EPS (TTM)-16.26
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est19.29
Trade prices are not sourced from all markets
  • Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations
    Market Realist3 days ago

    Jazz Pharmaceuticals’ 2018 Guidance and Analyst Recommendations

    Jazz Pharmaceuticals (JAZZ) estimates that in fiscal 2018, its net revenue will be $1.86 billion–$1.93 billion. Its estimated GAAP (generally accepted accounting principles) gross margin is 93% for 2018.

  • Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio
    Market Realist4 days ago

    Jazz Pharmaceuticals’ Xyrem, Erwinase, and Defitelio

    In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenues of $312.5 million compared to $291 million in 4Q16. In fiscal 2017, Xyrem reported revenues of $1.2 billion compared to $1.1 billion in 2016, which reflected a 7% growth on a YoY basis. Xyrem is used for the treatment of cataplexy in narcolepsy and excessive daytime sleepiness in narcolepsy.

  • Jazz Pharmaceuticals: How It’s Positioned before 1Q18
    Market Realist4 days ago

    Jazz Pharmaceuticals: How It’s Positioned before 1Q18

    In 4Q17, Jazz Pharmaceuticals (JAZZ) generated revenues of $436.4 million compared to $396.6 in 4Q16, which reflected a 10% growth on a YoY (year-over-year) basis and a 6% growth quarter-over-quarter.

  • Novartis’s 1Q18 Estimates: Expectations for Sandoz
    Market Realist4 days ago

    Novartis’s 1Q18 Estimates: Expectations for Sandoz

    Sandoz, the generics arm of Novartis (NVS), includes pharmaceuticals and biotechnological active substances in its portfolio. Sandoz is expected to report growth in operating revenue in 1Q18.

  • AbbVie’s Imbruvica in 4Q17 and Fiscal 2017
    Market Realist5 days ago

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter. In 4Q17, in US and international markets, Imbruvica reported revenue of $585 million and $123 million, respectively, reflecting ~35.3% and ~57.8% growth YoY.

  • 3 Top Healthcare Stocks to Buy in April
    Motley Fool9 days ago

    3 Top Healthcare Stocks to Buy in April

    April could be the perfect time to pick up shares in these top healthcare stocks.

  • Alexion to Acquire Wilson Therapeutics for $855 Million
    Market Realist9 days ago

    Alexion to Acquire Wilson Therapeutics for $855 Million

    On April 11, 2018, Alexion Pharmaceuticals (ALXN) announced that it has made a public cash offer to Wilson Therapeutics’ shareholders to acquire all of the company’s outstanding shares. Wilson Therapeutics is a Sweden-based biopharmaceuticals firm. The acquisition will advance Alexion’s long-term growth strategy, which consists of advancing and rebuilding its rare disease pipeline. Alexion aims to accelerate the diversification of its product portfolio.

  • Are Drug Prices Too Low?
    Bloomberg11 days ago

    Are Drug Prices Too Low?

    Generic makers say they may stop making medicines that don’t turn a profit.

  • Analyst Recommendations for Teva Pharmaceutical in April 2018
    Market Realist12 days ago

    Analyst Recommendations for Teva Pharmaceutical in April 2018

    In December 2017, the FDA accepted Teva Pharmaceutical Industries’ (TEVA) BLA (Biologics License Application) for fremanezumab for the preventive treatment of migraine. In February 2018, the European Medicines Agency accepted the MAA (Marketing Authorization Application) for fremanezumab for the treatment of adults with episodic and chronic migraine. In January 2018, the FDA approved Teva Pharmaceutical’s Trisenox and tretinoin combination therapy for the treatment of individuals with newly-diagnosed, low-risk APL (acute promyelocytic leukemia) with a presence of PML/RAR alpha gene expression.

  • A Look at Teva Pharmaceutical’s Specialty Medicines Segment
    Market Realist12 days ago

    A Look at Teva Pharmaceutical’s Specialty Medicines Segment

    In 4Q17, Teva Pharmaceutical Industries’ (TEVA) specialty medicines segment generated revenues of $1.8 billion compared to $2.2 billion in 4Q16. That was a 19% YoY (year-over-year) decline.

  • Teva Pharmaceutical’s Generic Medicines Segment in 2017
    Market Realist13 days ago

    Teva Pharmaceutical’s Generic Medicines Segment in 2017

    In fiscal 2017, Teva Pharmaceutical Industries’ (TEVA) generic medicines segment reported revenues of $12.3 billion compared to $12 billion in 2016, which was a 2% YoY (year-over-year) growth.

  • Teva Pharmaceutical’s Performance in 4Q17 and 2017
    Market Realist13 days ago

    Teva Pharmaceutical’s Performance in 4Q17 and 2017

    In 4Q17, Teva Pharmaceutical Industries (TEVA) reported revenues of $5.5 billion compared to $6.5 billion in 4Q16. That’s a 16% growth on a YoY (year-over-year) basis and a 3% growth on a quarter-over-quarter basis.

  • How Did Sandoz Perform in 4Q17 and Fiscal 2017?
    Market Realist20 days ago

    How Did Sandoz Perform in 4Q17 and Fiscal 2017?

    How Is Novartis Positioned after 4Q17?

  • How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed
    Market Realist20 days ago

    How Novartis’s Cardio-Metabolic and Neuroscience Segments Performed

    How Is Novartis Positioned after 4Q17?

  • How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17
    Market Realist24 days ago

    How Bristol-Myers Squibb’s Virology Drugs Performed in 4Q17

    What’s Behind Bristol-Myers Squibb’s Valuation

  • Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict
    Bloomberg25 days ago

    Teva Wins Ruling Tossing $235 Million Glaxo Drug Verdict

    Teva Pharmaceutical Industries Ltd. won a court ruling tossing a $235 million verdict over its copy of GlaxoSmithKline Plc’s Coreg heart drug.

  • Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018
    Market Realist26 days ago

    Teva Expects a Fall in Its Expenses and Cost Base in Fiscal 2018

    Recently, Teva Pharmaceutical (TEVA) has witnessed trouble in its business due to a number of company-specific and macroeconomic factors. The Copaxone sales decline due to generic competition, the pricing pressures in the market, and the impairments recently recorded by Teva are among the major factors triggering the company’s restructuring to recuperate the decline in its sales and earnings. For more information, read The Key Challenges Teva Pharmaceutical Is Facing.

  • GlobeNewswire26 days ago

    Analysis: Positioning to Benefit within PagSeguro Digital, Piedmont Office Realty Trust, Teva Pharmaceutical Industries, Obsidian Energy, HSBC Holdings plc, and ICICI Bank — Research Highlights Growth, Revenue, and Consolidated Results

    NEW YORK, March 27, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...

  • A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance
    Market Realist26 days ago

    A Look at Teva Pharmaceutical’s Fiscal 2018 Sales Guidance

    Investor Update: How Is Teva's Restructuring Plan Progressing?

  • How Does Teva Plan to Generate Cash Flows to Reduce Its Debt?
    Market Realist27 days ago

    How Does Teva Plan to Generate Cash Flows to Reduce Its Debt?

    As of December 31, 2017, Teva Pharmaceutical (TEVA) has debt of $32.5 billion compared to $35.8 billion at the end of 2016. The company has a debt payment of ~$3.5 billion due in fiscal 2018. Teva plans to pay down its debt using its operating cash flows and the cash flows resulting from its divestment of certain noncore and nonprofitable assets as part of its restructuring plan.

  • Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?
    Market Realist27 days ago

    Will Teva’s Fremanezumab Be Delayed due to Troubles at Celltrion?

    Teva Pharmaceutical (TEVA) has a number of key specialty assets that are touted as key long-term growth drivers for the company. Fremanezumab, a drug used for the treatment of migraines in adults, is one such product in the company’s specialty asset portfolio. The drug was accepted for review by the FDA in December 2017 and by the EMA (European Medicines Agency) in February 2018.

  • How Is Teva Progressing with Its Specialty Assets Portfolio?
    Market Realist27 days ago

    How Is Teva Progressing with Its Specialty Assets Portfolio?

    Teva Pharmaceutical (TEVA) is focused on advancing its specialty assets portfolio, one of its key growth drivers. The company’s specialty products portfolio is made up of Copaxone, Austedo, Fremanezumab, and a number of other assets that are in clinical trials, one of which is Fasinumab.

  • Teva Is Implementing This Strategy as Part of Its Restructuring
    Market Realistlast month

    Teva Is Implementing This Strategy as Part of Its Restructuring

    In December 2017, Teva Pharmaceutical (TEVA) laid down its restructuring plan, which included R&D (research and development) optimization involving the consolidation of its R&D sites while maintaining a robust R&D portfolio. For more details, read What’s Teva Pharmaceutical’s Research and Development Strategy? Since Teva laid out its restructuring plans, it has cut down 25 of its specialty area projects, representing ~27% of its R&D programs.

  • Impairments Drove Down Teva’s 2017 Profits: What to Expect
    Market Realistlast month

    Impairments Drove Down Teva’s 2017 Profits: What to Expect

    Teva Pharmaceuticals (TEVA) reported a GAAP (generally accepted accounting principles) operating loss of $13 billion in fiscal 4Q17, which it reported on February 8, 2018. This difference was the result of significant impairment charges related to Teva’s US generics business in fiscal 4Q17. In fiscal 4Q17, Teva recorded a non-GAAP adjustment of $15.3 billion, ~$11 billion of which was due to the impairment of goodwill related to the company’s US generics business.

  • Key Updates on Teva’s Restructuring Plan Progress
    Market Realistlast month

    Key Updates on Teva’s Restructuring Plan Progress

    Investor Update: How Is Teva's Restructuring Plan Progressing? Teva Pharmaceutical (TEVA) announced a restructuring plan in mid-December 2017. The announcement came after the company made some key leadership changes to recuperate from the dismal performance it saw over the last few quarters following its acquisition of Allergan’s (AGN) generics business and the negative impact of increasing generics business competition and pricing pressures.